UnitedHealth Group Q2 2025 earnings: costs squeeze profit, guidance restored
Revenue rose, but rising medical costs cut into profit; the CEO apologized and the company restored its full-year 2025 outlook.
| Q2 2025 | Reported |
|---|---|
| EPS | $3.74 |
| Revenue | $111.62B |
Figures as reported by the company to the SEC for the quarter ended June 30, 2025. Analyst estimates are not part of a filing, so no comparison to expectations is shown.
Key takeaways
- Revenue rose to $111.6 billion, up $12.8 billion from a year earlier, with growth in both the UnitedHealthcare insurance business and the Optum health-services business.
- The medical cost ratio — the share of premium income paid out for members’ medical claims — jumped to 89.4% from 85.1% a year earlier, meaning a much bigger slice of every premium dollar went to paying claims rather than covering overhead and profit.
- Management said the company absorbed roughly $6.5 billion in medical costs it had not priced for this year — about $3.6 billion from Medicare Advantage plans and $2.3 billion from commercial insurance — with additional pressure in Medicaid.
- Trailing-twelve-month figures show the same squeeze: operating margin sits at 4.74% and net profit margin at 3.14%, while earnings per share over that period are down about 33% from a year earlier, reflecting costs rising faster than premiums.
- CEO Stephen Hemsley, who returned to lead the company earlier in 2025, apologized to investors on the earnings call, saying the company made “pricing and operational mistakes” and that parts of the business need “fundamental reorientation.”
- Having suspended guidance in May amid rising costs and a leadership change, UnitedHealth reinstated a full-year 2025 outlook: revenue of $445.5 billion to $448 billion, adjusted earnings of at least $16.00 per share, and a full-year medical cost ratio expected near 89.25%.
- Shares fell more than 7% on the day of the report as investors reacted to the scale of the cost overruns and management’s comments.
- Return on equity over the trailing twelve months was 14.4% — still positive, but a sign that profitability has been squeezed by the higher costs described above.
Q2 2025 in context
| Metric | Jun 2025 | Jun 2024 | Change |
|---|---|---|---|
| Revenue | $111.6B | $98.9B | +12.9% |
| Net income | $3.4B | $4.2B | -19.2% |
| Free cash flow | $6.3B | $5.9B | +6.9% |
| Diluted EPS | $3.74 | $4.54 | -17.6% |
| Gross margin | 88.3% | 88.5% | -0.2 pts |
| Operating margin | 4.6% | 8.0% | -3.4 pts |
| Net margin | 3.1% | 4.3% | -1.2 pts |
Figures for the quarter ended Jun 2025 and the quarter ended Jun 2024, as reported to the SEC.
Each company's quarter ending in calendar Q2 '25, as reported to the SEC. A peer that reported no revenue figure for that quarter is left out.
How the stock took it
UnitedHealth Group Incorporated closed at $250.89 on Aug 8, 2025, the last session before the report, and at $261.57 on Aug 12, 2025, the first session after it — +4.3% across the report.
Closes from the market's daily record. Each figure spans the report date — from the last session that closed before it to the first that closed after — because a company may report before the open or after the close.
Sources: company report · CNBC · Becker's Payer Issues